We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
+2.58%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$347M
AUM Growth
+$226M
Cap. Flow
+$218M
Cap. Flow %
62.97%
Top 10 Hldgs %
99.96%
Holding
12
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PMVP icon
PMV Pharmaceuticals
PMVP
+$238M

Top Sells

Rank Stock Value
1
REAL icon
The RealReal
REAL
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.91%
2 Consumer Discretionary 16.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$62.9M
$230M 66.28%
+6,469,911
New +$238M
REAL icon
2
The RealReal
REAL
$1.4B
$55.8M 16.09%
3,854,080
-1,300,000
-25% -$19.9M
GKOS icon
3
Glaukos
GKOS
$8.92B
$32M 9.24%
646,364
– –
AGTC
4
DELISTED
Applied Genetic Technologies Corporation
AGTC
$7.08M 2.04%
1,455,904
– –
EIGR
5
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.23M 1.8%
25,497
– –
STIM icon
6
Neuronetics
STIM
$126M
$5.01M 1.45%
1,030,689
– –
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$4.89M 1.41%
388,766
– –
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$3.87M 1.12%
67,841
– –
VERO
9
DELISTED
Venus Concept
VERO
$1.53M 0.44%
3,992
– –
HIND
10
Vyome Holdings
HIND
$14M
– –
0
– –
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.36B
$92K 0.03%
8,293
– –
DARE icon
12
Dare Bioscience
DARE
$19.8M
$50K 0.01%
4,197
– –

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q3 2020 Portfolio in Review

As of Q3 2020, InterWest Venture Management held 12 positions worth $347M, up 187% from $121M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management deployed $218M of net new capital in Q3 2020, opening 1 new position. Its largest new stake was PMV Pharmaceuticals: 6,469,911 shares worth $230M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 45% a quarter earlier, followed by Consumer Discretionary.

On the sell side, the largest reduction was The RealReal, an estimated $19.9M trimmed.

  • InterWest Venture Management's largest Q3 2020 buy was PMV Pharmaceuticals: 6,469,911 shares worth $230M.
  • InterWest Venture Management's biggest Q3 2020 reduction was The RealReal, cutting an estimated $19.9M.
  • InterWest Venture Management's ten largest holdings make up 100% of its $347M portfolio in Q3 2020.
  • InterWest Venture Management opened 1 new position and closed 0 in Q3 2020.
  • InterWest Venture Management's portfolio value rose 187% quarter-over-quarter to $347M.

Based on InterWest Venture Management's 13F filing for Q3 2020, filed 15 Oct 2020.